UNSPSC 51432807: Enalaprilat anhydrous

This classification denotes an ace inhibitor with the molecular formula C18H24N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q508Q118JM, chemically known as l-proline, 1-(n-(1-carboxy-3-phenylpropyl)-l-alanyl)-, (s)-, but more generally known as enalaprilat anhydrous, which bears US NIH Compound Identifier 5362033. European Medicines Agency schedules enalaprilat anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06515MIG.

Most nations, for tariff purposes, schedule enalaprilat anhydrous under HS 29339990. Enalaprilat anhydrous bears US NLM identifiers UMLS ID C0886809 and NCI Concept Code C76135. SMILES: C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2CCCCC2)C(=O)O.

UNSPSC 51432807 Enalaprilat anhydrous, a Commodity code, covers injectable cardiovascular and emergency-care medications supplied to state and local emergency-response and healthcare organizations. State and local governments procure these pharmaceuticals primarily through fire rescue departments, public health agencies, and cooperative purchasing alliances that serve multiple jurisdictions. Recent solicitations show a focus on direct supply of finished medications to emergency medical services, with vendors competing on price, product availability, compliance with pharmaceutical manufacturing standards, and ability to meet strict expiration-date and shelf-life requirements.

The code sees activity across multiple states, with recent opportunities posted by the City of Tampa (Florida), the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (serving Minnesota and Oregon). The City of Tampa's Advanced Life Support Medications IFB (26P00188, due April 8, 2026, estimated value $40,000) solicited multiple emergency-care injectable medications for use by Tampa Fire Rescue, with firm pricing including shipping, a one-year contract term, and a 5 percent SLBE bid discount not to exceed $10,000. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) sought manufacturers to supply generic pharmaceuticals and OTC products through three authorized wholesalers for a two-year term, with pricing evaluated at 75 percent weight and compliance with cGMP, DSCSA, and FDA requirements mandatory. Texas HHS issued an RFI (HHS0017013, April 3, 2026) to explore direct-to-manufacturer prescription programs that could reshape procurement strategy for state pharmacy benefit programs. Vendors should expect compliance requirements including Safety Data Sheets per OSHA standards, accessibility documentation for digital materials, comprehensive insurance coverage, and performance penalties for late reporting or missed timelines.